A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of JANX011 With Optional Step-Up Dosing in Healthy Adult Volunteers
Latest Information Update: 10 Mar 2026
At a glance
- Drugs JANX 011 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Janux Therapeutics
Most Recent Events
- 26 Feb 2026 According to Janux Therapeutics media release, Company expects to announce an initial clinical update from the Phase 1 study of JANX011 in healthy volunteers by year-end 2026.
- 17 Feb 2026 According to Janux Therapeutics media release, first patient has been dosed.
- 17 Feb 2026 According to Janux Therapeutics media release,status changed from not yet recruiting to recruiting.